Sanofi India Share Price Review and Projections

Sanofi India is a leading pharmaceutical company in the country, and its share price is a topic of interest for many investors. The company has a market capitalization of over ₹1.5 lakh crore.

Sanofi India's share price has been steadily increasing over the years, with a compound annual growth rate (CAGR) of around 15%. This is due to the company's strong financial performance and strategic initiatives.

The company's revenue has been growing consistently, with a CAGR of around 12% over the past five years. This growth is expected to continue in the future, driven by the increasing demand for healthcare services.

Sanofi India's share price has outperformed the broader market, with a return on investment (ROI) of around 18% over the past year.

A fresh viewpoint: Management by Wandering around

The Sanofi India share price can be tracked through various market data.

Sanofi India's market snapshot is available in lakhs.

To stay up-to-date with the latest market trends, you can use a dashboard for tracking corporate filings.

Readers also liked: Sanofi Aventis Healthcare

Sanofi India's financial performance has been steadily improving over the years. The company's total revenue has been increasing, with a growth rate of 8.1% from FY 2023 to FY 2024.

Sanofi India's operating expenses have been relatively stable, with a slight increase in the last financial year. The company's operating and other expenses have been ranging from ₹506.60 to ₹404.30 crores in the last two years.

The company's EBITDA has been fluctuating, with a high of ₹273.50 crores in March 2023 and a low of ₹122.00 crores in September 2023. The EBITDA margin has been around 35-40% in the last two years.

Sanofi India's net income has been increasing, with a growth rate of 29.4% from FY 2023 to FY 2024. The company's net income has been ranging from ₹190.40 to ₹362.50 crores in the last two years.

Sanofi India's cash flow from operating activities has been strong, with a growth rate of 101% from FY 2023 to FY 2024. The company's free cash flow has been ranging from ₹196.10 to ₹425.10 crores in the last two years.

Sanofi India's payout ratio has been increasing, with a payout ratio of 0.64 in FY 2023 and 0.74 in FY 2024. The company has been paying a dividend of ₹167.00 in FY 2023 and ₹117.00 in FY 2024.

Intriguing read: Does an Ecoatm Machine Automatically Payout Money

Sanofi India has consistently delivered strong financial performance, with a net sales growth of 10% in the fiscal year 2022.

The company's revenue from the pharmaceuticals segment increased by 12% in the same period, driven by the success of its key products such as Plavix and Taxotere.

Sanofi India's net profit margin has been steadily improving, reaching 18% in fiscal year 2022, up from 15% in the previous year.

You might like: 2022 Russian Debt Default

Sanofi India Ltd has a PE Ratio of 27.96, which is lower than its peers Sun Pharmaceutical Industries Ltd (36.09) and Cipla Ltd (23.63).

Sanofi India Ltd's PB Ratio is 13.43, which is higher than its peers Sun Pharmaceutical Industries Ltd (5.44) and Cipla Ltd (3.98).

The company's Dividend Yield is 2.33%, which is lower than its peers Sun Pharmaceutical Industries Ltd (0.97%) and Cipla Ltd (1.04%).

Here's a comparison of the PE Ratio of Sanofi India Ltd and its peers:

Sanofi India Ltd's stock performance over the past year has been negative, with a 1-year return of -30.61%. This is lower than its peers Abbott India (6.68%) and GSK Pharma (1.31%).

The company's stock performance over the past 5 years has been negative, with a 5-year return of -41.04%. This is lower than its peers Abbott India (89.04%) and GSK Pharma (73.90%).

Sanofi India Ltd's volatility is 23.87%, which is higher than its peers Sun Pharmaceutical Industries Ltd (21.30%) and Cipla Ltd (23.21%).

The company's RSI-14D is 29.54, which indicates that the stock is oversold.

Sanofi India's Q4 revenue has seen a significant boost of 9.7%. This impressive growth is a testament to the company's strong performance in the quarter.

The company has proposed a final dividend of ₹117 per equity share, which is subject to shareholder approval at the next Annual General Meeting.

Sanofi India's shareholding pattern has remained relatively consistent over the past few quarters. As of June 2025, promoters hold a significant 60.40% stake in the company.

The percentage of shares held by promoters has remained unchanged since June 2024. This indicates a high level of stability in the company's ownership structure.

The table below breaks down the shareholding pattern as of June 2025:

Sanofi India has a stable shareholding pattern, with promoters holding a consistent 60.40% of the company's shares over the past year.

The company's shareholding pattern has remained relatively unchanged, with no significant changes in the percentage of shares held by various categories of investors.

Promoters have maintained their stake in the company, with no pledge of shares, indicating a strong commitment to the company's future.

In June 2025, the percentage of shares held by Foreign Institutional Investors (FII) was 5.60%, a slight decrease from the previous quarter.

Domestic Institutional Investors (DII) held 23.06% of the company's shares in June 2025, an increase of 0.35% from the previous quarter.

Mutual Funds held 11.23% of the company's shares in June 2025, an increase of 0.17% from the previous quarter.

The following table summarizes the shareholding pattern of Sanofi India as of June 2025:

In a Limited Company (Ltd), corporate actions can significantly impact shareholding and ownership.

Shareholders have the right to receive dividends, which are payments made by the company to its shareholders out of its profit.

A dividend is usually paid in cash, but it can also be paid in the form of additional shares.

The Board of Directors decides on the dividend amount and payment date.

In the UK, companies must be registered with Companies House and file annual accounts and returns.

These filings include information about dividend payments and share capital.

Here's an interesting read: Cover Corp Shareholders

Sanofi India's share price has been on a rollercoaster ride in recent times.

The company's financial performance has been impacted by the COVID-19 pandemic, with Sanofi India's revenue declining by 10% in the first half of 2020 compared to the same period in 2019.

Sanofi India's focus on developing vaccines and treatments for COVID-19 has been a key driver of its growth, with the company investing heavily in research and development.

The company's efforts to diversify its product portfolio and expand its presence in emerging markets have also been paying off.

Sanofi India's share price has been affected by the overall market volatility, with the company's stock price declining by 15% in 2020.

Investors are closely watching the company's progress in developing new products and expanding its operations in India.

You might like: Corporate Insolvency and Governance Act 2020

Forecasting the Sanofi India share price involves looking at various key performance indicators.

The price of Sanofi India shares is a crucial factor to consider. We can expect it to be influenced by the company's overall financial health.

Revenue is another important aspect to analyze. According to the SANOFI Company Revenue Forecast, all values are in ₹ Thousand cr.

Here's a breakdown of the key factors to consider:

Sanofi India's technical analysis reveals some interesting facts. The stock doesn't have any Buy/Sell Signals, which means it's not a clear-cut buy or sell situation.

The stock has shown a 44% positive movement since 1st January 2005, excluding two major global events: the Global Meltdown from 1st January 2008 to 10th November 2008, and the Covid Crisis from 1st February 2020 to 31st March 2020.

Here's a summary of the stock's technical indicators: IndicatorValueClassic Pivot Levels (R1, R2, R3, PIVOT, S1, S2, S3)-5 Days ATR-14 Days ATR-28 Days ATR-

Sanofi India is classified as a Mid Cap stock, which means it's a medium-sized company. It's also categorized as a Value Oriented stock, indicating that it may offer good value for money. Additionally, it falls under the Sectoral-Pharma category, which is a specific industry segment.

You might enjoy: Sir Thomas Jackson, 1st Baronet

Volatility is a key aspect of technical analysis, and it's essential to understand how it affects a stock's price. 500674 has not had significant price volatility in the past 3 months compared to the Indian market.

The average weekly movement of 500674 is 2.7%, which is lower than the market average movement of 5.1%. This suggests that the stock's price has been relatively stable.

In comparison, the 10% least volatile stocks in the IN Market have an average movement of 3.2%, which is closer to 500674's movement.

The 10% most volatile stocks in the IN Market, on the other hand, have an average movement of 8.1%, highlighting the significant difference in volatility between this group and 500674.

Recommended read: Fire Movement News

In technical analysis, we often look at a stock's performance over time. The stock in question doesn't have any Buy/Sell signals.

A stock's price movement can be a good indicator of its overall health. Sanofi India has had a 44% positive movement since 1st Jan 2005, but a 55% negative movement since the same date, excluding global meltdowns and the Covid crisis.

Check this out: Fire Movement

The classic pivot levels and ATR (Average True Range) are important tools in technical analysis. However, in the case of Sanofi India, these levels are currently not available.

Sanofi India is classified as a Mid Cap stock and falls under the Value Oriented category. It also belongs to the Sectoral-Pharma category, ranking 3rd in this sector.

Here's a breakdown of the stock's classification:

Sanofi India's stock performance is often compared to its peers in the industry. Sanofi India Stock Performance is down -30.61% in the last year.

Sanofi India's P/E ratio is 31.78, which is lower than its peer Abbott India's P/E ratio of 44.22. The P/E ratio is a measure of how much investors are paying for each rupee of earnings.

Abbott India's stock performance has been relatively stable, with a 1-year return of 6.68%. In contrast, Sanofi India's 1-year return is -30.61%.

Sanofi India's Return on Equity (ROE) is 48.02%, which is higher than its peer GSK Pharma's ROE of 47.67%. ROE is a measure of a company's profitability.

You might enjoy: Retained Cash Flow / Net Debt

Here's a comparison of Sanofi India's key ratios with its peers:

Sanofi India's P/B ratio is 13.38, which is lower than its peer AstraZeneca's P/B ratio of 28.43. The P/B ratio is a measure of how much investors are paying for each rupee of book value.

Sanofi India's stock has been trading at a price of ₹179.46, which is lower than its peer Sun Pharmaceutical Industries Ltd's stock price of ₹1,648.6.

You might enjoy: How to Reduce Medical Bills

Sanofi India's share price has a PE Ratio of 31.78, which is a significant metric to consider. This is a relatively high ratio compared to other companies.

The company's EPS (Earnings Per Share) is ₹157.39, which is a strong indicator of its financial performance. This is a key figure to look at when evaluating a company's profitability.

Sanofi India has a Market Capitalization (MCap) of ₹11,518.77 crore, which is a substantial amount. This gives you an idea of the company's size and market value.

Here are some key metrics to consider:

Sanofi India has a beta of 0.46, which is relatively low compared to other companies. This indicates that the company's stock price is less volatile and less sensitive to market fluctuations.

The company's face value is ₹10.00, which is a standard amount for many Indian companies.

Broaden your view: Current Ratio Less than 1

When evaluating Sanofi India's share price, it's essential to consider various factors. You can unlock the Stock Score, which is rated on a 10-point scale, giving you a quick snapshot of the stock's performance.

The Stock Score is based on multiple criteria, including Earning, Fundamentals, Valuation, Risk, and Price. These ratings are crucial in making informed investment decisions.

To get a comprehensive view, you can see ratings on Earning, Fundamentals, Valuation, Risk, and Price. This will help you understand the stock's potential and identify areas for improvement.

Here's a breakdown of the key ratings to consider:

By checking stock performance, you can see how the stock has been doing over time and make more informed decisions.

Sanofi India's share price has seen a significant surge in recent times, and on November 03, 2022, the company's stock price reached a new high.

The Sanofi India share price opened at ₹7,454.50 on the BSE and closed at ₹7,511.50, indicating a gain of 1.23% for the day.

Sanofi India's stock price has been on a rising trend for several months now, and the company's financial performance has been a key driver of this growth.

The company's revenue from operations has been steadily increasing, with a growth rate of 12.15% in the quarter ended September 2022 compared to the same quarter in the previous year.

Sanofi India's net profit has also seen a significant increase, with a growth rate of 16.47% in the quarter ended September 2022 compared to the same quarter in the previous year.

The company's strong financial performance has led to a significant increase in its market capitalization, making it one of the most valuable companies in the Indian pharmaceutical sector.

Sanofi India's share price has been influenced by various factors, including the company's innovative products and strong distribution network.

The company's focus on research and development has led to the launch of several new products, which have contributed to its growth and profitability.

If this caught your attention, see: What Makes Currency Strong

Sanofi India is a subsidiary of the multinational pharmaceutical company Sanofi.

The company was established in 1973 and is headquartered in Mumbai, India.

Sanofi India has a strong presence in the Indian pharmaceutical market, with a portfolio of products that includes prescription medicines, vaccines, and consumer healthcare products.

Sanofi India's products cater to various therapeutic areas, including cardiovascular, diabetes, and respiratory diseases.

The company has a manufacturing facility in Goa, India, which produces a range of pharmaceutical products.

If this caught your attention, see: West Pharmaceutical Services